Similar articles

• [Anticoagulation in atrial fibrillation].

  Binggeli C, Brunckhorst CB. Binggeli C, et al. Herz. 2008 Feb;33(1):13-9. doi: 10.1007/s00059-008-3090-8. Herz. 2008. PMID: 18273573 Review. German.
• Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.

  Tincani E, Baldini P, Crowther MA, Zanasi A, Ferrari P, Cenci AM, Rioli G. Tincani E, et al. Blood Coagul Fibrinolysis. 2009 Jan;20(1):47-51. doi: 10.1097/MBC.0b013e32831be9da. Blood Coagul Fibrinolysis. 2009. PMID: 20523164
• Stroke prevention versus bleeding risk of vitamin-K antagonists: a double-edged sword in patients with atrial fibrillation who require surgery.

  Dobrev D, Goette A, Ravens U. Dobrev D, et al. Cardiovasc Ther. 2009 Winter;27(4):223-5. doi: 10.1111/j.1755-5922.2009.00110.x. Cardiovasc Ther. 2009. PMID: 19903184
• Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation.

  Tay KH, Lip GY, Lane DA. Tay KH, et al. Blood Coagul Fibrinolysis. 2009 Jul;20(5):392-3. doi: 10.1097/MBC.0b013e32832aec47. Blood Coagul Fibrinolysis. 2009. PMID: 19542940 No abstract available.
• Clinical practice. Care of patients receiving long-term anticoagulant therapy.

  Schulman S. Schulman S. N Engl J Med. 2003 Aug 14;349(7):675-83. doi: 10.1056/NEJMcp025373. N Engl J Med. 2003. PMID: 12917305 Review. No abstract available.